key: cord-0306767-4bdgo9vu
authors: Amaral-Silva, Daniela; Torrão, Rita C.; Torres, Rita; Falcão, Sandra; Gonçalves, Maria João; Araújo, Maria Paula; Martins, Maria José; Lopes, Carina; Neto, Agna; Marona, José; Costa, Tiago; Castelão, Walter; Silva, Ana Bento; Silva, Inês; Lourenço, Maria Helena; Mateus, Margarida; Gonçalves, Nuno Pina; Manica, Santiago; Costa, Manuela; Pimentel-Santos, Fernando; Mourão, Ana Filipa; Branco, Jaime C.; Soares, Helena
title: Direct tissue sensing reprograms TLR4+ Tfh-like cells inflammatory profile in the joints of rheumatoid arthritis patients
date: 2021-02-20
journal: bioRxiv
DOI: 10.1101/2021.02.19.431679
sha: 93da224f7cece029c0296888c7999fba852db205
doc_id: 306767
cord_uid: 4bdgo9vu

CD4+ T cells mediate rheumatoid arthritis (RA) pathogenesis through both antibody-dependent and independent mechanisms. It remains unclear how synovial microenvironment impinges on CD4+ T cells pathogenic functions. Here, we identified a TLR4+ follicular helper T (Tfh) cell-like population present in the blood and expanded in synovial fluid. Mechanistically, we unveiled that homotypic T-T cell interactions through non-cognate HLA-DR:TCR contacts regulate TLR4 expression on T cells. TLR4+ T cells possess a two-pronged pathogenic activity. Upon TCR and ICOS engagement, TLR4+ T cells produce IL-21, a cytokine known to sponsor antibody production. However, direct TLR4+ engagement on T cells, by endogenous ligands in the arthritic joint, reprograms them towards an IL-17 inflammatory profile compatible with tissue damage program. Blocking TLR4 signaling with a specific inhibitor impaired IL-17 production in response to synovial fluid recognition. Ex vivo, synovial fluid TLR4+ T cells produced IL-17, but not IL-21. TLR4+ T cells appear to uniquely reconcile an ability to promote systemic antibody production with a local synovial driven tissue damage program. TLR4+ T cells could constitute an attractive cellular target and predictive biomarker for erosive arthritis.

In rheumatoid arthritis (RA) combined immune and joint tissue dysregulation 44 synergize in propagating chronic inflammation and articular destruction. CD4 + T 45 cells have been strongly implicated in RA pathogenesis through both antibody-46 dependent and independent mechanisms 1,2 . It remains unclear, however, which 47 CD4 + T cell population drives RA and how joint microenvironment impinges on 48 their pathogenic functions. Unveiling CD4 + T cell pathogenic phenotype and its 49 crosstalk with the arthritic joint environment would benefit diagnosis, patient 50 stratification and could contribute to the design of better drugs that could 51 effectively induce remission. 52

Effector functions sponsored by CD4 T cells in the joints constitute an active field 53 of research. PD-1 high CXCR5 high T follicular helper (Tfh) cells are the major T cell 54 subset driving antibody production by B cells within secondary lymphoid 55 organs 3,4 . Even though circulating Tfh cell populations are diverse 5 , they have 56 been defined as CXCR5 + 6,7 and/or PD-1 + CXCR5 + 8 . In RA, various circulating 57

Tfh cell populations have been correlated with B cell expansion and increased 58 disease activity 9-11 . Recently, PD-1 + CXCR5 -T cells, which share several markers 59 with Tfh cells, were reported to infiltrate the inflamed synovium and to induce 60 antibody production in vitro 12 . Notwithstanding, CD4 + T cell mediated antibody-61 TLR4 + CD4 + T cells co-expressed HLA-DR. When looking at their cellular 218 abundance, higher expression of HLA-DR was accompanied by greater TLR4 219 expression (Fig. 3D ). Taken together, the above data suggested that there might 220 be a link between HLA-DR and TLR4 expression. 

Tfh-like T cells have been implicated in RA and other chronic inflammatory 239 diseases due to their capability to induce antibody production 11, 12, 42 . We checked 240

whether TLR4 + T cells would share Tfh features, namely high expression of 241 chemokine receptor CXCR5 and of the co-receptors PD-1 (Fig. 1J) and ICOS. 242 Even though CXCR5 (Fig. 4 A-C) and PD-1 (Fig. 4 A, D, E) could be detected in 243 both TLR4and TLR4 + T cell populations, they were enriched in TLR4 + T cells 244 with a co-expression of ~80% (Fig. 4F) . Curiously, ICOS was more expressed in 245 TLR4than in TLR4 + T cells (Fig. 4 A, G, H) . Nonetheless, in TLR4 + T cells co-246 expression of ICOS and CXCR5 (Fig. 4H ) and ICOS and PD-1 (Fig. 4J) was 247 enriched. The fact that TLR4 + T cells are enriched of CXCR5 and PD-1 suggests 248 that they might consist a circulating Tfh-like population 6, 7 . To characterize this 249 further, we explored whether the enrichment in TLR4 + T cells could reflect the 250 frequency of circulating Tfh cells. TLR4 + T cell frequency positively correlated 251 with the frequency of CXCR5 + (Fig. 2K ) and PD-1 + (Fig. 2L ) circulating CD4 + T 252

These data indicate that TLR4 + T cells display Tfh-like features. 254 255 TLR4 + T cells display migratory phenotype to inflamed tissues 256 TLR4 + T cell enrichment in synovial fluid ( Fig. 1 G, H) cannot be fully explained 257 by their CXCR5 expression. Therefore, we checked for the expression of 258 chemokine receptors CCR2 and CCR6 that regulate T cell migration to inflamed 259 tissues and whose ligands are abundantly present in arthritic synovium and have 260 been implicated in the disease 43, 44 . Both CCR2 and CCR6 were upregulated by 261 TLR4 + T cells (Fig 5 B-E) . CCR2 and CCR6 are expressed by ~100% and ~30% 262 of TLR4 + T cells, respectively . While CCR2 guides a broad range of 263 immune cells into sites of inflammation, CCR6 is associated with the recruitment 264 of IL-17 producing T cells to inflamed joints 45 , suggesting an IL-17 inflammatory 265 component to TLR4 + T cell synovial recruitment. To address this possibility, we 266 checked whether TLR4 + T cells upregulate receptors for pro-inflammatory 12 cytokines that are overexpressed in inflamed synovium (IL-1, IL-6 and IL-17) and 268 which have been implicated in IL-17 production 45, 46 . IL-1R, whose engagement 269 plays a critical in driving IL-17 mediated autoimmunity 46 , was selectively 270 upregulated by TLR4 + T cells (Fig. 5 A, H, I). As expected from IL-6 pleiotropic 271 role in immune responses, IL-6R was similarly expressed by both TLR4 + and 272 TLR4 -T cell populations (Fig. 5 F, J, K) . Finally, IL-17R, whose signaling 273 reinforces IL-17 production and CD4 + T cells autoimmune profile 47 , was greatly 274 enriched in TLR4 + T cells (Fig. 5 G, L, M) . In addition, since TLR4 + T cells 275 displayed a bigger cell size, we checked for the receptor of IL-2 alpha (IL-2Ra), 276 whose ligation drives T cell growth. IL-2R was increasingly expressed by TLR4 + 277 (Fig. 5 N, O) . 278

Taken together TLR4 + T cells emerge as a Tfh-like cell population with a 279 preferential tropism for inflamed tissues and increased capability to respond to 280 IL-17 promoting stimuli. Curiously, TLR4 + T cells are not predisposed to respond 281 to IL-6, which is involved in driving both Tfh cell differentiation 48 and IL-17 282 production 45 , that is a current RA treatment target. Instead, TLR4 + T cells are 283 predisposed to preferentially respond to IL-1 and IL-17. Due to the involvement 284 of both IL-1R and IL-17R signaling in promoting chronic inflammatory IL-17 285 responses 46,47 , selective increased expression of these receptors might ascribe 286 a dysregulated IL-17 producing profile to TLR4 + T cells. 287

While in humans, the role of direct TLR4 engagement on CD4 + T cells remains 290 largely unaddressed, in experimental autoimmune encephalitis, TLR4 291 engagement on CD4 + T cells has been reported to function as a co-receptor 292 13 boosting T cell survival and proliferation without affecting the amount of the 293 cytokines produced 31 . Whether or not direct TLR4 engagement on CD4 + T cells 294 modulates or alters CD4 + T cell inflammatory profile has remained unanswered. 295

To unveil the contribution of direct TLR4 engagement on T cell inflammatory 296 profile, we FACS purified circulating CD4 + T cells from freshly obtained blood ( Fig  297   S1B ; purity >99%) and stimulated them with highly purified TLR4 ligand LPS in 298 the presence or absence of TCR and ICOS engagement. Since we had 299 determined that TLR4 + T cells share features of Tfh-like cells and possess an IL-300 17 flavored pro-inflammatory phenotype, we looked at the antibody inducing 301 cytokines which have been in RA pathology due to their role in promoting 302 antibody production (IL-21 12 and IL-10 60 ), or in inducing joint tissue damage (IL-303 10 61 , 19, 49, 50 and TNF-a 59 ). Circulating TLR4 + T cells produced IL-10, IL-304 21 and IL-17 in unstimulated conditions, supporting their ongoing activation state. 305

In vitro, IL-21 production required TCR and ICOS stimulation and was completely 306 non-responsive to LPS (Fig. 6 A, B) . In contrast, LPS, in combination with TCR 307 and ICOS stimulation, boosted IL-10, IL-17 and TNF-a production . 308

Moreover, LPS alone was sufficient to drive production of IL-10 and trended to 309 increase IL-17 and TNF-a production, as well (Fig. 6 C, G) . 310

In sum, these data indicate that direct TLR4 stimulation goes beyond functioning 311 as a coreceptor boosting TCR-driven response. While TCR and ICOS stimulation 312 favors IL-21 production, LPS engagement shifts the inflammatory profile toward 313 IL-17, TNF-a and of IL-10 production. Suggesting that TLR4 engagement by LPS 314 might reprogram TLR4 + T cells from an IL-21 driven pro-antibody program to an 315 inflammatory program fueling joint damage 316 317 Discussion 368 RA is a chronic inflammatory disease where CD4 + T cells and joint tissue 369 dysregulation synergize in propagating chronic inflammation and articular 370 destruction. Treatment of RA remains challenging as identity of CD4 + T cell 371 population driving RA and the mechanism by which joint microenvironment 372 impinges dysregulated T cell activation remain elusive. Here, we identified a 373 circulating TLR4 + T cell population which is enriched in synovial fluid of RA 374 patients. TLR4 + T cells are uniquely attuned to respond distinctly to different 375 contextual cues. They reconcile an unique ability to potentially promote systemic 376 antibody production with an synovial-driven tissue damage program. Our results 377 highlight the contribution of spatial compartmentalization, including homotypic 378 cell:cell contacts, to T cell driven pathogenicity and the role of tissue environment 379 in tailoring site-specific T cell responses. 380

Tfh-like cell populations have been described in several chronic inflammatory 381 diseases including in rheumatoid arthritis 2 , lupus nephritis 58 and systemic 382 sclerosis 59 . In addition in RA, a population of IL-21 producing and antibody 383 inducing peripheral helper T (Tph) cells has been identified 12 . Here we have 384 identified a previously unknown Tfh-like population. TLR4 + T cells were enriched 385 in Tfh cell markers, CXCR5 and PD-1 6-8 and their frequency in circulation 386 correlated with anti-CCP antibody levels. These sets of Tfh/Tph cells might 387 indeed account for distinct cell populations or might represent the same cell 388 population in different disease stages and/or response to treatment. Distinctly 389 from previous reports 2,12,58,59 , we analyzed freshly obtained blood and synovial 390 fluid samples, rather than frozen ones. Fresh samples facilitate the identification 391 of infrequent cell populations and the detection of certain markers and allow for 392 a better detection of changes in cell size and shape. 393

Early descriptions of TLR4 + T had similarly reported an increase in cell size 60 TLR4 is a relatively promiscuous immune sensor that recognizes both microbial 441 and endogenous ligands. In ankylosing spondylitis patients, CD28 -TLR4 + T cells 442 with a senescent phenotype were found to be present in the blood but practically 443 absent from affected joints 39 . This is in stark contrast with the TLR4 + Tfh-like cell 444 population reported here; TLR4 + T cells were expanded in synovial fluid, and 445 even though they were enriched for PD-1 they did not exhibit signs of wither 446 exhaustion or senescence, as illustrated by their highly proliferative status and 447 increased ability to produce cytokines in response to stimulation. In addition to 448 CXCR5, TLR4 + T cells also expressed the chemokine receptors CCR2 and CCR6 449 indicating a preferential recruitment to inflamed tissues, which might account for 450 their enrichment in the affected joints. Interestingly, TLR4 signaling has been 451 reported to augment cell migration and invasiveness 70,71 , opening the possibility 452 that direct TLR4 engagement could propel T cell invasiveness into affected joint. 453

In mice models of autoimmune diseases TLR4 signaling in CD4 + T cells has been 454 reported to function both as disease facilitator 31 and protector 30 . Nonetheless, a 455 role for direct TLR4 engagement in T cell cytokine profile and function had not 456 been reported so far. Our data show that while TCR engagement favors 457 production of antibody inducing cytokine IL-21, TLR4 engagement by either LPS 458 or synovial fluid components ensues IL-17, IL-10 and TNF-a production, cytokine 459 whose role in RA has been ascribed to promoting joint damage 15, 19, 49, 50, 59, 61 . Even 460 though IL-10 is often labeled as an anti-inflammatory cytokine, it is well 461 established that IL-10 has both immunosuppressive and stimulatory effects, 462 including cytotoxic activity against tumors 72 . In RA, IL-10 has been reported to 463 drive inflammatory arthritis and joint destruction 73 . The existence of an antibody-464 20 independent pathogenic function for TLR4 + T cells would explain why this 465 population is also present in seronegative RA patients. 466

Curiously, while TLR4 engagement by LPS functions as a costimulatory signal 467 boosting TCR signaling, TLR4 ligation by endogenous TLR4 ligands fuels TLR4 + 468 T cell inflammatory program independently of cognate antigen recognition. 469

Distinct ligands ensuing different TLR4 responses is likely due to the fact that 470 TLR4 has multiple binding sites 55 . In fact, TLR4 ligation by endogenous ligands 471

Tenascin-C and fibronectin is not blocked by an LPS mimetic, which blocks TLR4 472 activation by competing with LPS for TLR4/MD-2 binding 26,74 . In addition, gene IL-17, IL-10 and TFN-a production. Thus, we can conclude that the production of 478 IL-17, IL-10 and TNF-a induced by synovial fluid is specifically mediated by TLR4 479 on T cells. It is likely that these TLR4 sponsored effects are mediated by the 480 combined action of several endogenous TLR4 ligands present in the joints. 481

Importantly, ex vivo freshly analyzed synovial TLR4 + T cells seemed to be 482 skewed toward IL-17 production. When compared to in vitro stimulation with cell-483 depleted synovial fluid, synovial TLR4 + T cells seemed to be poised to produce 484 more IL-17, less IL-10 and no TNF-a. These differences might be due to the fact 485 that to release cells from synovial fluid, it is necessary to degrade it enzymatically. 486

Hyaluronidase digestion could give rise to additional TLR4 ligands that could be 487 more adept at inducing IL-10 and TNF-a in in vitro restimulation assays. In 488 particular, different molecular weight hyaluronic acid fragments are known to elicit 489 distinct inflammatory profiles 75 . It is possible that in vivo, IL-17 is the main 490 cytokine induced by direct engagement of TLR4 on synovial T cells, where it 491 might play a prominent role in mediating bone erosions and cartilage damage 76, 77 . 492

Our study recruited a considerable RA patient cohort of 103 patients. 493

Nonetheless, there are some limitations to our study. We could only obtain a 494 relatively modest number of synovial fluid samples. This was due to the fact that 495 we only used freshly obtained synovial fluid whose access to was seriously 496 hindered during this last year COVID-19 pandemic imposed serious restrictions 497 on hospital access to chronic patients. Another limitation was that most of the 498 patients recruited were either in remission or presented controlled disease and 499 thus had very low DAS scores, which made difficult to correlate the frequency of 500 TLR4 + T cells with disease activity. Despite these limitations, TLR4 + T cells in the 501 blood and synovial fluids correlated well indicating that the blood can be used to 502

probe TLR4 + T cell synovial enrichment. In addition, our functional assays were 503 robust identifying a causal relationship linking TLR4 + T cells selective recognition 504 of joint tissue environment to the type immune profile ensued. Further studies will 505 be needed to address the impact of TLR4 + T cells in joint damage. 506

Deciphering which CD4 + T cells are relevant to the disease process and they 507 interplay with the joint microenvironment is a critical hurdle to our understanding 508 of RA. Here we propose a mechanism by which the joint tissue microenvironment 509 might reset on TLR4 + T cells pathological function. Outside the joints, TLR4 + Tfh-510 like cells will be activated predominantly through the TCR leading to the 511 production of IL-21, which favors antibody production and will likely contribute to 512 anti-CCP antibody titers (Fig. 8) . Within in the affected joints homotypic T:T cell 513 interactions mediated through non-cognate HLA-DR:TCR coupling supports 514 TLR4 surface expression. In turn, direct sensing of joint damage patterns by 515 TLR4 + T cells reprograms them towards an IL-17 pathological program that drives 516 and sustains cartilage damage and bone erosions (Fig.8 ). This two-prong 517 mechanism could highlight several attractive therapeutic targets both at the 518 systemic level and in the affected tissues. In addition, circulating TLR4 + T cells 519 could constitute a good biomarker to predict flares and possibly which patients 520 are more likely to develop cartilage damage and joint erosions. 

The authors declare no competing interests. 547

The Ethics Committee of NOVA Medical School and of Hospital Egas Moniz 551 approved this study. Informed consent was obtained from RA patients that 552 fulfilled ACR 2010 classification criteria. Rheumatoid factor status, C-reactive 553 protein level, erythrocyte sedimentation rate and medication usage were obtained 554 by review of medical records. Anti-CCP antibody titers were determined at the 555 time of blood draw using a commercial assay anti-CCP ELISA (IgG) from 556 EUROIMMUN with a positive result defined as >5RU/mL. Number of swollen 557 and/or tender joints was measured by attending clinician on the day of sample 558 acquisition. Treatments are categorized in: non-steroid anti-inflammatory 559 (NSAID), corticosteroids, disease modifying antirheumatic drugs (DMARDs) and 560

biological DMARDs (dDMARDs). Blood was drawn by venipuncture into Lithium-561

Heparin containing cell preparation tubes (BD, Vacutainer). Synovial fluid was 562 collected only when excess material from patients undergoing diagnostic or 563 therapeutic arthrocentesis. Demographic and clinical data for all the patients 564 enrolled in this study are listed in Table S1 . 565 566 567

Blood samples and synovial fluid were processed within 2 hours of collection and 569 freshly analyzed. Peripheral blood and synovial mononuclear cells were isolated 570 by density gradient centrifugation (Biocoll, Merck Millipore) or following enzymatic 571 digestion with hyaluronidase (10µL/mL; 30min at 37ºC), respectively. Plasma and 572 cell-depleted synovial fluid were frozen until further use. 573 574

For flow cytometry analysis peripheral blood cells were stained with antibodies 576 listed in Table S2 . For cell viability, Fixable Viability Dye (eBioscience) or Calcein populations cell purity was routinely >98% (Fig. S1C ). For intracellular cytokines 588 assays sorted CD3 high CD4 high , rested for at least 3h, were stimulated with 5 µg/mL 589 of anti-CD3 (UCHT1, BioLegend) and 2 µg/mL of anti-ICOS (C398.4A, 590

BioLegend), crosslinked with 5 µg/mL anti-mouse IgG1 (BioLegend) plus 10 591 µg/mL anti-hamster IgG (Thermo Fisher Scientific) at 37ºC in the presence of 592

Brefeldin-A (Life Technologies) for 14 h. Cells were fixed in paraformaldehyde 593 1% (Sigma-Aldrich) and permeabilized with saponin (Carl Roth). Antibodies used 594 are listed in Table S2 . When indicated 1.7 µg/mL LPS (Sigma-Aldrich) or cell-595 depleted synovial fluid (SF) was added. For TLR4 blocking, CLI-095 (InvivoGen) 596 was added at 10 µg/mL 1h before stimulation. Cell sorting was performed in a BD 597

FACSAria III instrument (BD Biosciences). 598 599 Imaging, image processing, and quantification 600 FACS-purified CD3 high CD4 high HLA-DR + cells were immediately plated onto poly-601 L-lysine-coated coverslips, fixed in 4% paraformaldehyde for 15 min at room 602 temperature, incubated with blocking buffer (PBS BSA 1%) and immunostained 603 as previously described 33, 78 . Antibodies used for immunofluorescence staining 604 are described in Table S2 . Confocal images were obtained using a Zeiss LSM 605 710 confocal microscope (Carl Zeiss) over a 63x objective. Z stack optical 606 sections were acquired at 0.2 μm depth increments, and both green and red laser 607 excitation were intercalated to minimize crosstalk between the acquired 608 fluorescence channels. 3D image deconvolution was performed using Huygens 609 Essential 19.10, and 2D images were generated from a maximum intensity 610 projection over a 3D volume cut of 0.4-µm depth centered on the cell medium 611 plane using Imaris. For quantification of cell size and roundness, confocal images 612 were acquired at 2-μm increments in the z-axis. 613 614

Flow cytometry data was analyzed using FlowJo and pluggins DownSample and 616

FlowAI. The flow cytometry data was compensated at the time of acquisition with 617

UltraComp eBeads (Thermo Fisher). As controls unstained and fluorescence 618 minus one (FMO) conditions were included. The data collected in .fcs files was 619 analyzed so that all abnormal events would be excluded by using FlowAI (Gianni 620 R29-11 (2010) . 685

Lubberts, E. The IL-23-IL-17 axis in inflammatory arthritis. Nature 686

Reviews Rheumatology 11, 415-429 (2015) . Rheum 58, 1931-1939 (2008 Arthritis Res. Ther. 14, R260-9 (2012) . 

Single-Cell Sorting. Cytometry 8, e46045-9 (2020). 831

Nat Immunol 4, 815-815 (2003) . 833

produce IFN-gamma by an IL-12-independent but CD70-dependent 835 mechanism in vivo. J Exp Med 204, 1095-1106 (2007) . 836

The Wellcome Trust Case Control Consortium. Genome-wide 837 association study of 14,000 cases of seven common diseases and 838 3,000 shared controls. Nature 447, 661-678 (2007) . From top to bottom: a population of TLR4 + Tfh-like T cells expanded in synovial fluid of RA patients was characterized in a cohort of more than 100 RA patients. We uncovered a function for HLA-DR expression by T cells, as homotypic T:T cell contacts established through HLA-DR:TCR were found to be required for TLR4 expression by T cells. TLR4 + T cells display a two-pronged mechanism uniquely poised to tailor their pathogenic phenotype in response to contextual cues. Outside the joints, TCR driven IL-21 production favors antibody production, which likely contributes to anti-CCP antibody titers. Within in the affected joints direct sensing of joint damage patterns by TLR4 + T cells reprograms them towards an IL-17 pathological program known to drive and sustain cartilage damage and bone erosions. 

Anti-hamster IgG Thermo Fisher Scientific Cat#31115

BioLegend Cat#307602

C398-4A) BioLegend Cat#313512

Anti-TLR4 (76B357.1) Abcam Cat#ab22048

RPA-T4) BioLegend Cat#300506 (FITC)

L243) BioLegend Cat#307606 (PE)

HTA125) BioLegend Cat#312805 (PE)

MAb11) Biolegend Cat#502926 (PerCP/Cy5.5)

K036C2) BioLegend Cat#357211 (PeCy7)

Anti-CD25 (M-A251) BioLegend Cat#356107 (PeCy7)

B56) BD Pharmigen Cat#561283

MAb11) BioLegend Cat#502929 (PeCy7)

Anti-IL-10 (JES3-9D7) BioLegend Cat#501419

RPA-T4) BioLegend Cat#300514 (APC)

Anti-IL6R (UV4) BioLegend Cat#352805 (APC)

C398.4A) BioLegend Cat#313510 (APC)

BG/hIL17AR) BioLegend Cat#340903 (A647)

Anti-IL-21 (3A3-N2) BioLegend Cat#513006 (A647)

Anti-mouse IgG1 Thermo Fisher Cat#A21240 (A647)

HIT3a) BioLegend Cat#300318 (APC-Cy7)

G034E3) BioLegend Cat#353432 (APC-Cy7)

HIT2) BioLegend Cat#303533 (APC-Cy7)

J252D4) BioLegend Cat#356925 (APC-Cy7)

Anti-IL17 (BL168) Biolegend Cat#512320 (APC-Cy7)

SK7) BioLegend Cat#344828 (Bv510)

BioLegend Cat#3448284 (PB)

Anti-mouse IgG2b Thermo Fisher Cat#A21141 (A488)

From top to bottom: a population of TLR4 + Tfh-like T cells expanded in synovial 1074 fluid of RA patients was characterized in a cohort of more than 100 RA patients. 1075We uncovered a function for HLA-DR expression by T cells, as homotypic T:T 1076 cell contacts established through HLA-DR:TCR were found to be required for 1077

uniquely poised to tailor their pathogenic phenotype in response to contextual 1079 cues. Outside the joints, TCR driven IL-21 production favors antibody production,